Targeting and increasing the number of T cells resulting from blocking the PD-1/PD-L interaction could be a primary mechanism in immunotherapy for cancer [115], but in therapeutic strategies, energy deficiencies and translational issues in exhausted T cells may also be significant [116]. Here, PDCD1 is linked to cancer.